GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Results] 70 weeks on 2.4mg, full numbers, ask me anything boring — 12 comments in the full submission. View in context.
-24
c/orforglipron·submitted 1 year ago by u/ines_lindqvist

[Results] 70 weeks on 2.4mg, full numbers, ask me anything boring

Speculationbranch of 8 comments

Update, and the title has the headline: 70 weeks on 2.4mg, full numbers, ask me anything boring. 70 weeks and 2.4mg. Those are measured, not estimated, and not rounded up in my favour. What is actually known, and what is being assumed. Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical…

Read the full submission and all 12 comments →

This branch

8 comments, started 1 year ago
u/lucia_bruun3 points·1 year ago

It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.

replysharereportpermalink
u/trialwatch_theoMOD2 points·1 year ago

Corrected a cross-class dose comparison in the title. The body is untouched.

replysharereportpermalink
u/ines_lindqvistOP1 point·1 year ago

Correction: that is the oral peptide product, which is a different thing entirely. This one is a small molecule.

replysharereportpermalink
[removed]1 point·1 year ago

[removed by moderator]

replysharereportpermalink
u/ines_lindqvistOP1 point·1 year ago

Milligram-for-milligram comparison with an injectable peptide is not meaningful and I should not have made it.

replysharereportpermalink
u/incretin_ivypharmacology1 point·1 year ago

the boards keep comparing it to injectables at matched doses, which is meaningless

replysharereportpermalink
u/dilara_weiss1 point·1 year ago

The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.

replysharereportpermalink
u/brigade_detector1 point·1 year ago

a non-peptide agonist does not degrade the way a peptide does

replysharereportpermalink

← back to the whole thread

About c/orforglipron

The small-molecule oral: why a non-peptide agonist escapes the absorption problems of oral semaglutide, what the ATTAIN and ACHIEVE readouts showed, and what a pill with no refrigeration requirement would do to the entire supply conversation this site is built around.

21kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/orforglipron rules
  1. Small molecule, not a peptide. Purity discussion here is a different problem.
  2. Cite ATTAIN/ACHIEVE arms specifically when quoting numbers.
  3. Availability speculation must be flaired Speculation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.